204 related articles for article (PubMed ID: 33422910)
1. Design, synthesis and anti-inflammatory activity of imidazol-5-yl pyridine derivatives as p38α/MAPK14 inhibitor.
Ali EMH; Abdel-Maksoud MS; Hassan RM; Mersal KI; Ammar UM; Se-In C; He-Soo H; Kim HK; Lee A; Lee KT; Oh CH
Bioorg Med Chem; 2021 Feb; 31():115969. PubMed ID: 33422910
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAF
Ali EMH; El-Telbany RFA; Abdel-Maksoud MS; Ammar UM; Mersal KI; Zaraei SO; El-Gamal MI; Choi SI; Lee KT; Kim HK; Lee KH; Oh CH
Eur J Med Chem; 2021 Apr; 215():113277. PubMed ID: 33601311
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, p38α MAP kinase inhibition, anti-inflammatory activity, and molecular docking studies of 1,2,4-triazole-based benzothiazole-2-amines.
Tariq S; Alam O; Amir M
Arch Pharm (Weinheim); 2018 Apr; 351(3-4):e1700304. PubMed ID: 29611883
[TBL] [Abstract][Full Text] [Related]
4. Repurposing mosloflavone/5,6,7-trimethoxyflavone-resveratrol hybrids: Discovery of novel p38-α MAPK inhibitors as potent interceptors of macrophage-dependent production of proinflammatory mediators.
Hassan AHE; Yoo SY; Lee KW; Yoon YM; Ryu HW; Jeong Y; Shin JS; Kang SY; Kim SY; Lee HH; Park BY; Lee KT; Lee YS
Eur J Med Chem; 2019 Oct; 180():253-267. PubMed ID: 31310917
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, evaluation and docking of novel pyrazolo pyrimidines as potent p38α MAP kinase inhibitors with improved anti-inflammatory, ulcerogenic and TNF-α inhibitory properties.
Somakala K; Tariq S; Amir M
Bioorg Chem; 2019 Jun; 87():550-559. PubMed ID: 30928877
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological testing of N-aminoimidazole-based p38alpha MAP kinase inhibitors.
Bracht C; Hauser DR; Schattel V; Albrecht W; Laufer SA
ChemMedChem; 2010 Jul; 5(7):1134-42. PubMed ID: 20473979
[TBL] [Abstract][Full Text] [Related]
7. Structural optimization of 4-(imidazol-5-yl)pyridine derivatives affords broad-spectrum anticancer agents with selective B-RAF
Ali EMH; Mersal KI; Ammar UM; Zaraei SO; Abdel-Maksoud MS; El-Gamal MI; Haque MM; Das T; Kim EE; Lee JS; Lee KH; Kim HK; Oh CH
Eur J Pharm Sci; 2022 Apr; 171():106115. PubMed ID: 34995782
[TBL] [Abstract][Full Text] [Related]
8. Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases.
Muth F; Günther M; Bauer SM; Döring E; Fischer S; Maier J; Drückes P; Köppler J; Trappe J; Rothbauer U; Koch P; Laufer SA
J Med Chem; 2015 Jan; 58(1):443-56. PubMed ID: 25475894
[TBL] [Abstract][Full Text] [Related]
9. Unexpected reaction of 2-alkylsulfanylimidazoles to imidazol-2-ones: pyridinylimidazol-2-ones as novel potent p38alpha mitogen-activated protein kinase inhibitors.
Koch P; Laufer S
J Med Chem; 2010 Jun; 53(12):4798-802. PubMed ID: 20481631
[TBL] [Abstract][Full Text] [Related]
10. Anticancer profile and anti-inflammatory effect of new N-(2-((4-(1,3-diphenyl-1H-pyrazol-4-yl)pyridine sulfonamide derivatives.
Abdel-Maksoud MS; Mohamed Hassan R; Abdel-Sattar El-Azzouny A; Nabil Aboul-Enein M; Oh CH
Bioorg Chem; 2021 Dec; 117():105424. PubMed ID: 34678604
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase.
Kim DK; Lim JH; Lee JA; Dewang PM
Bioorg Med Chem Lett; 2008 Jul; 18(14):4006-10. PubMed ID: 18571921
[TBL] [Abstract][Full Text] [Related]
12. CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities.
Trifilieff A; Keller TH; Press NJ; Howe T; Gedeck P; Beer D; Walker C
Br J Pharmacol; 2005 Apr; 144(7):1002-10. PubMed ID: 15685201
[TBL] [Abstract][Full Text] [Related]
13. Imidazole inhibitors of cytokine release: probing substituents in the 2 position.
Laufer SA; Striegel HG; Wagner GK
J Med Chem; 2002 Oct; 45(21):4695-705. PubMed ID: 12361396
[TBL] [Abstract][Full Text] [Related]
14. From 2-Alkylsulfanylimidazoles to 2-Alkylimidazoles: An Approach towards Metabolically More Stable p38α MAP Kinase Inhibitors.
Heider F; Haun U; Döring E; Kudolo M; Sessler C; Albrecht W; Laufer S; Koch P
Molecules; 2017 Oct; 22(10):. PubMed ID: 29036906
[TBL] [Abstract][Full Text] [Related]
15. Pyridinylimidazoles as dual glycogen synthase kinase 3β/p38α mitogen-activated protein kinase inhibitors.
Heider F; Ansideri F; Tesch R; Pantsar T; Haun U; Döring E; Kudolo M; Poso A; Albrecht W; Laufer SA; Koch P
Eur J Med Chem; 2019 Aug; 175():309-329. PubMed ID: 31096153
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of N-cyclopropylbenzamide-benzophenone hybrids as novel and selective p38 mitogen activated protein kinase (MAPK) inhibitors.
Heo J; Shin H; Lee J; Kim T; Inn KS; Kim NJ
Bioorg Med Chem Lett; 2015 Sep; 25(17):3694-8. PubMed ID: 26115577
[TBL] [Abstract][Full Text] [Related]
17. Fluorescence polarization-based assays for detecting compounds binding to inactive c-Jun N-terminal kinase 3 and p38α mitogen-activated protein kinase.
Ansideri F; Lange A; El-Gokha A; Boeckler FM; Koch P
Anal Biochem; 2016 Jun; 503():28-40. PubMed ID: 26954235
[TBL] [Abstract][Full Text] [Related]
18. 1,2,4-Triazole-based benzothiazole/benzoxazole derivatives: Design, synthesis, p38α MAP kinase inhibition, anti-inflammatory activity and molecular docking studies.
Tariq S; Kamboj P; Alam O; Amir M
Bioorg Chem; 2018 Dec; 81():630-641. PubMed ID: 30253336
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, in vitro Antiproliferative and Antiinflammatory Activities, and Kinase Inhibitory effects of New 1,3,4-triarylpyrazole Derivatives.
El-Gamal MI; Abdel-Maksoud MS; Gamal El-Din MM; Shin JS; Lee KT; Yoo KH; Oh CH
Anticancer Agents Med Chem; 2017; 17(1):75-84. PubMed ID: 27334850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
